Enzyme Immunoassay (E), Radioimmunoassay (R), Immunocytochemistry/Immunofluorescence (ICC/IF)
Background of Haloperidol antibody
Haloperidol is a butyrophenone antipsychotic drug that has strong central antidopaminergic activity. It has pharmacological effects similar to the phenothiazines. The drug exhibits high affinity dopamine D2 receptor antagonism and slow receptor dissociation kinetics.Haloperidol's negligible affinity for histamine H1 receptors and muscarinic M1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain, and orthostatic hypotension though having higher rates of treatment emergent extrapyramidal symptoms. Tradenames are: Aloperidin, Bioperidolo, Brotopon, Dozic, Duraperidol, Einalon S, Eukystol, Haldol, Halosten, Keselan, Linton, Peluces, Serenace, Serenase, and Sigaperidol.
Granger, Bernard; Albu, Simona (2005). "The Haloperidol Story". Annals of Clinical Psychiatry 17 (3): 137–40. PMID 16433054.
Seeman, P; Tallerico, T (1998). "Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors". Molecular Psychiatry 3 (2): 123–34. PMID 9577836.
Leysen, JE; Janssen, PM; Gommeren, W; Wynants, J; Pauwels, PJ; Janssen, PA (1992). "In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone". Molecular Pharmacology 41 (3): 494–508. PMID 1372084